AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calcium/calmodulin-dependent protein kinase kinase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96RR4

UPID:

KKCC2_HUMAN

Alternative names:

Calcium/calmodulin-dependent protein kinase kinase beta

Alternative UPACC:

Q96RR4; A8K7Q7; O94883; Q8IUG2; Q8IUG3; Q8N3I4; Q8WY03; Q8WY04; Q8WY05; Q8WY06; Q96RP1; Q96RP2; Q96RR3; Q9BWE9; Q9UER3; Q9UES2; Q9Y5N2

Background:

Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) plays a pivotal role in cellular processes through a calcium-triggered signaling cascade. It phosphorylates various targets including CAMK1, CAMK4, and AMPK, responding to calcium signals. This kinase is involved in hippocampal activation of CREB1 and influences neurite growth, with different isoforms promoting branching or elongation.

Therapeutic significance:

Understanding the role of Calcium/calmodulin-dependent protein kinase kinase 2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.